"The prototype is expected in the third quarter of 2020, in the fourth quarter it is planned to begin preclinical studies on animals," RIA Novosti quoted an expert from the research institute.
He specified that it is planned to test the vaccine in mice, studies will take several months, and its appearance as a registered drug is expected in mid-2021.
The institute noted that COVID-19 practically does not mutate, so the vaccine created will be relevant at the time of registration.
According to the specialist, most likely, the drug will protect people of all ages.
Earlier, the World Health Organization (WHO) announced that more than 20 coronavirus vaccines are being developed in the world.